Evidence map›Paper›PMID 42182864›Full record

ArticleMaterials today. Bio2026

Multifunctional scaffold based on Ti

Yihui Zhang, Wenkai Zhang, Zeyuan Xie, Wei Yu, Xiangqi Zhang, Yangwen Luo, Muge Gu, Jiayu Wang, Wei-En Yuan, Yebin Qian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yihui ZhangEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Wenkai ZhangEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Zeyuan XieEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Wei YuEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Xiangqi ZhangEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yangwen LuoEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Muge GuEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Jiayu WangEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Wei-En YuanEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yebin QianDepartment of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Volumetric muscle loss (VML) regeneration remains clinically challenging, primarily due to compromised myogenic differentiation and an oxidative-inflammatory microenvironment that impedes regeneration. Consequently, timely resolution of inflammation and dynamic remodeling of the immune niche are imperative for functional VML recovery. Ti

Indexed as

AntioxidantMicroenvironment managementMuscle regenerationTi3C2Tx MXene

Identifiers

PMID42182864
PMCPMC13194544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.